Cardiogenic Shock Intravascular Cooling Trial (CHILL-SHOCK).

Area of Science:

• Cardiology
• Critical Care Medicine
• Therapeutic Hypothermia

Background:

• Cardiogenic shock (CS) is associated with high mortality rates.
• Targeted temperature control (TTC) is being investigated as a potential adjunctive therapy for CS.
• The safety of TTC in CS patients requires thorough examination.

Purpose of the Study:

• To evaluate the safety of targeted temperature control (TTC) as an adjunct therapy in patients with cardiogenic shock (CS).
• To assess the impact of TTC on hemodynamic parameters and mortality in CS patients.

Main Methods:

• An open-label, randomized controlled pilot trial involving 20 patients with CS.
• Patients were assigned to either standard care plus TTC or standard care alone.
• Primary outcome was a composite safety assessment; secondary outcomes included mortality, hemodynamic measures, and inotrope use.

Main Results:

• No significant difference in prespecified safety outcomes between the TTC and control groups (3 events vs. 0 events, P=0.24).
• Patients receiving TTC showed statistically significant improvements in cardiac index and cardiac power index at 48-96 hours.
• Improvements in cardiac index (3.6 vs. 2.6 L/min/m²; P=0.029) and cardiac power index (0.61 vs. 0.53 W/m²; P=0.029) were observed.

Conclusions:

• Targeted temperature control (TTC) may be a safe adjunctive therapy for patients experiencing cardiogenic shock (CS).
• TTC demonstrated potential to improve key hemodynamic parameters in CS patients.
• Further research is warranted to confirm the benefits and safety of TTC in CS management.